Risk factors
Atea Pharmaceuticals (AVIR) risk factors
Item 1A of every Atea Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors94 risks7 new11 dropped23 reworded
Late-stage HCV development now includes commercial launch supply manufacturing and NDA preparation for bemnifosbuvir/ruzasvir.
Filed Mar 05, 2026 - FY2024 10-K risk factors98 risks
Atea Pharmaceuticals is a clinical-stage antiviral company relying primarily on the development of the bemnifosbuvir and ruzasvir regimen for HCV.
Filed Mar 06, 2025